CN1060336C - Medicine for prevention and treatment of calcium deficiency and its prepn - Google Patents
Medicine for prevention and treatment of calcium deficiency and its prepn Download PDFInfo
- Publication number
- CN1060336C CN1060336C CN95117811A CN95117811A CN1060336C CN 1060336 C CN1060336 C CN 1060336C CN 95117811 A CN95117811 A CN 95117811A CN 95117811 A CN95117811 A CN 95117811A CN 1060336 C CN1060336 C CN 1060336C
- Authority
- CN
- China
- Prior art keywords
- medicine
- calcium
- treatment
- calcium deficiency
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 206010006956 Calcium deficiency Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims description 43
- 229940079593 drug Drugs 0.000 title description 9
- 230000002265 prevention Effects 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 9
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 9
- 239000004220 glutamic acid Substances 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 8
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 8
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 8
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 8
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 8
- 235000001465 calcium Nutrition 0.000 claims description 47
- 239000007788 liquid Substances 0.000 claims description 18
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 150000001669 calcium Chemical class 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 47
- 239000011575 calcium Substances 0.000 abstract description 47
- 229910052791 calcium Inorganic materials 0.000 abstract description 47
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 18
- 208000001132 Osteoporosis Diseases 0.000 abstract description 9
- 208000007442 rickets Diseases 0.000 abstract description 9
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000009529 zinc sulphate Nutrition 0.000 abstract 1
- 239000011686 zinc sulphate Substances 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 45
- 230000000694 effects Effects 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 16
- 239000004227 calcium gluconate Substances 0.000 description 11
- 229960004494 calcium gluconate Drugs 0.000 description 11
- 235000013927 calcium gluconate Nutrition 0.000 description 11
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 11
- 239000000047 product Substances 0.000 description 8
- 208000008035 Back Pain Diseases 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 229960001763 zinc sulfate Drugs 0.000 description 6
- 229910000368 zinc sulfate Inorganic materials 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 238000002562 urinalysis Methods 0.000 description 5
- 208000008930 Low Back Pain Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 102000014823 calbindin Human genes 0.000 description 2
- 108060001061 calbindin Proteins 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940023492 oral liquid product Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicine for preventing and curing calcium deficiency, and a preparation method for the medicine. The medicine is prepared by that 4 to 8 parts of soluble calcium agent, 0.1 to 0.4 part of zinc gluconate or zinc sulphate, 0.8 to 1.2 parts of glutamine or glutamic acid, and water are mixed by a weight ratio of 3 to 9:100, filtered and sterilized. The medicine of the present invention has the advantages of convenient taking and good absorption, increases blood calcium and has an obvious therapeutic effect on child rickets and adult osteoporosis.
Description
The present invention relates to a kind of medicine of preventing and treating treatment of calcium deficiency and preparation method thereof.
Treatment of calcium deficiency is the medical problem that people generally face.Data shows, has infant about 70% to have in various degree calcium deficiency at present in the world, and it is a lot of that therefore infant is suffered from the rickets patient, in China's patient's ratio up to 25%; 50% people need replenish calcium preparation among the anemia of pregnant woman, and the calcium deficiency of fetal period more and more causes people's attention, and the anemia of pregnant woman will replenish calcium has become conventional health care regulations; Osteoporosis is a kind of commonly encountered diseases of old people, especially postmenopausal women, there is 26% people to suffer from osteoporosis approximately, its symptom mostly is lumbar and back pain, and stature becomes short and fracture etc., has had a strong impact on old people's live and work, increasing along with long-lived population from now on, suffering from osteoporotic number also will increase day by day, expect 2000, and its proportion will increase to 17% from 8%.At this problem of human body treatment of calcium deficiency, people have developed various edible calcium preparation, as calcium gluconate, calcium lactate, calcium chloride or the like, but normal person's intestinal only can absorb 3% of the amount of eating, therefore, though a lot of patients take calcium preparation, can not reach good therapeutic effect owing to absorption difference.
The objective of the invention is to overcome the shortcoming of prior art and provide a kind of absorb fast, effective, taking convenience, nontoxic pair of effect a kind of to prevent or treat medicine of treatment of calcium deficiency and preparation method thereof.
The object of the present invention is achieved like this, selects following ingredient and weight ratio thereof for use:
4-8 parts of solubility calcium preparation
0.1-0.4 part in zinc gluconate or zinc sulfate
0.8-1.2 parts in glutamine or glutamic acid
The solubility calcium preparation is optional with calcium gluconate, calcium chloride, calcium lactate, calcium carbonate or activated calcium.
When making oral liquid, the weight ratio of its water and described medicine is 100: 3-9.
The formula optimization weight proportion scope of preparation medicine of the present invention is:
4-7 parts of solubility calcium preparation
0.2-0.3 part in zinc gluconate or zinc sulfate
0.8-1 part in glutamine or glutamic acid
When making oral liquid, the preferred weight proportioning of its water and described medicine is 100: 3-7.
Medicine optimum weight of the present invention
5 parts of solubility calcium preparation
0.25 part in zinc gluconate or zinc sulfate
1 part in glutamine or glutamic acid
When making oral liquid, the optimum weight proportioning of water and described medicine is 100: 5.
Wherein be convenient to behind the solubility calcium preparation water dissolution absorb, directly increase and take in calcium, glutamine or glutamic acid are the key component of mucous membrane of small intestine calbindin, it can make small intestinal calbindin content increase, and promotes that calcium is shifted in blood vessel by small intestinal, increases the absorption of calcium at small intestinal, trace element zinc is grown skeletal growth important Nutrition, this effect is by somatomedin, and stimulating appetite increases and to realize proteinic synthesizing.
Its preparation method is as follows, in Agitation Tank, add deionized water, be heated to 100 ℃, pour the solubility calcium preparation in described ratio, zinc gluconate or zinc sulfate, glutamine or glutamic acid, stir, dissolving, mixing adds deionized water again, and the part by weight that makes Total Water and medicine is 100: 3-9, use the sintered glass filter of 80-120 μ m to filter then, fill becomes bottle, 10 milliliters every, High Temperature High Pressure or microwave sterilizating, this is oral liquid product of the present invention, certainly, if the said medicine composition is mixed evenly, adds adjuvant and make powder, incapsulate product also of the present invention.
The instructions of taking of this oral liquid is as follows, 1 of child below 3 years old every day; 3-12 years old child every days twice, each 1; Every day three times more than 12 years old, each 1 or according to state of an illness dosage, one month is a course of treatment.Powder and capsule is followed the doctor's advice.
Product of the present invention was once done acute toxinology experiment, and lumbar injection LD50 is 147 9mg/kg, and toxic reaction does not take place 6000mg/kg when irritating stomach, shows that its toxicity is little.This product route of administration is oral, is a kind of foolproof medicine therefore.This product is done long term toxicity test and is proved, little, in, during big three kinds of dosed administrations 90 days and drug withdrawal observed in 21 days, compare with matched group, rat body weight, appetite, hemogram, blood biochemistry index, main organs weight all do not have significant difference, heavy dose of group is all no abnormal with the matched group histological examination, show that fully this product is a kind of foolproof medicine, but life-time service.For further this product of clinical verification curative effect with have no adverse reaction,
Medicine of the present invention once to children rachitis and adult's osteoporosis, carried out observation of curative effect in different hospitals, and existing division is as follows:
The observation of curative effect of treatment osteoporosis
One, case is selected: 55 routine patients are my the pain clinic patient of institute, male 29 examples, women 26 examples.21-79 years old ages.Average 57 ± 10.48 years old.Observe 40 examples, matched group 15 examples.
Two, observation index: lumbago, have a pain in the leg, movable difficulty, numb, symptoms such as tic.(Chvostek levies the back percussion pain and Trosseau such as levies at sign.Blood, calcium, concentration, X line (lumbar vertebra) blood, routine urinalysis, liver, renal function.
Three, evaluation criterion: produce effects, treatment back symptom, sign have improvement more than 2/3, and blood calcium rises greater than 0.125mmol/L or rises to normal range; Effectively: treatment back symptom and sign alleviates 1/3-2/3, blood calcium rising 0.025mmol/L-0.125mmol/L; Invalid: treatment back symptom and sign does not have improvement, and blood calcium concentration does not raise.
Four, observational technique: observation group, osteotrophy liquid (oral liquid of the present invention, down together) 10ml every day below 3 years old, 3-14 years old, 2 times on the one, each 10ml was grown up 3 times on the one, each 10ml, 15 days courses of treatment.Matched group, calcium gluconate tablet (BJ Pharmaceutical Co., Ltd.), below 3 years old, every day 600mg, 3-14 years old every days 2 times, each 600mg, per day for adults 3 times, each 600mg, 15 days courses of treatment.
Five, experimental result
Method: selecting has typical osteoporotic patient 55 examples through what the X line was made a definite diagnosis, is divided into 2 groups of 1. matched group 15 examples at random, male 6 examples, women 9 examples, 59.7+6.7 year.2. observation group, male 23 examples, women 17 examples, 54.3 ± 9.6 years old.Before medication and medication the 15th day the last observation index of crossing is measured.
The result
(1) treatment back symptom and sign improves situation
The variation of the table 1 treatment two groups of patient's clinical manifestations in back
| Lumbago and skelalgia is alleviated lumbago and skelalgia and is not alleviated |
| Matched group 96 observation groups 38 2 |
X
2=10．75 P＜0．01
(2) two groups of patients in treatment back, the variation of calcium level
The variation of calcium level before and after the table 2 liang group treatment
| Treatment back t p before the treatment |
| Matched group 2.11 ± 0.30 2.32 ± 0.21 3.89＜0.05 observation group 2.21 ± 0.18 2.49 ± 0.16 6.67＜0.01 |
After treatment, two groups of calcium levels all rise
The comparison of table 3 liang group blood calcium rising spoke degree
| Blood calcium rising spoke degree t p |
| Matched group 0.14 ± 0.16 2.31＜0.05 observation group 0.26 ± 0.12 |
From table 2, can see that after the treatment of osteotrophy liquid, observation group's blood calcium increases obvious than matched group.
(3) two groups of observation of curative effect
Table 4 liang group treatment back curative effect relatively
| Produce effects enabledisable obvious effective rate (%) |
| Matched group 3 10 2 20% treatments organize 35 41 87.5% |
X
2=10．75 P＜0．05
Discuss: osteoporosis is a kind of commonly encountered diseases, and good sending out in the old people especially after women's menopause, can cause, lumbago and backache is fractured and limitation of activity, has a strong impact on old people's quality of life.Confirmed at present to replenish the calcium and to have prevented and treated osteoporosis effectively, improved patient's symptom.Calcium preparation in the market is more, but the calcium preparation of good absorbing seldom.Osteotrophy liquid promptly contains calcium; Contain calcium absorption enhancer again, and be liquid dosage form, therefore, good absorbing, taking convenience, this experimental result shows that it can obviously improve osteoporotic symptom.
Conclusion:
1, this experimental result shows, osteotrophy liquid has the obvious effect that improves the osteoporosis symptom, and its curative effect is better than calcium gluconate tablet.
2, the medication front and back are to blood, routine urinalysis, and the detection of hepatic and renal function shows that this medicine is without any side effects.
3, this medicine is a liquid dosage form, taking convenience.
The observation of curative effect of treatment rickets of child
One, case is selected: 50 routine infants are my institute's department of pediatrics and are in hospital and the outpatient male 28 examples, women 22 examples.1.5 months-12 years old age, observation group's 35 examples, matched group 15 examples.
Two, observation index: hyperhidrosis, easy frightened, sleep disorder, twitch and symptom such as numbness, rest the head on baldly, Chvostk levies, and Trosseau such as levies at sign; The variation of blood calcium, phosphorus, alkali phosphatase, X line; The hematuria routine, liver, renal function.
Three, evaluation criterion: produce effects, treatment back symptom, sign have improvement more than 2/3, and blood calcium rises greater than 0.125mmol/L or rises to normal range; Effectively, treatment back symptom and sign alleviates 1/3-2/3, blood calcium rising 0.025mmol/L-0.125mmol/L; Invalid, treatment back symptom and sign does not have improvement, and blood calcium concentration does not raise.
Four, observational technique: observation group, osteotrophy liquid (oral liquid of the present invention, down together) 10ml every day below 3 years old; 3-14 years old, 2 times on the one, each 10ml, 15 days courses of treatment.Matched group, calcium gluconate tablet (BJ Pharmaceutical Co., Ltd.), below 3 years old, every day 600mg, 3-14 years old every days 2 times, each 600mg, 15 days is a course of treatment.
Five, experimental result
Method: select to have infant 50 examples of typical rickets performance, all cases are all through medical history, and clinical manifestation and blood calcium, phosphorus, alkali phosphatase and X line are made a definite diagnosis, and do not have other concomitant disease during dispensing, and infant is divided into observation group and matched group at random.1. matched group 15 examples, male 9 examples, women 6 examples, 1.4 ± 1.0 years old age.2. observation group's 35 examples, male 19 examples, women 16 examples, 1.3 ± 1.2 years old age.Before medication,, the last observation index of crossing is measured with medication the 15th day.
Six, result
(1) treatment back clinical symptoms is improved (table 1)
The variation of the table 1 treatment two groups of infant clinical manifestations in back
| Hyperhidrosis * easily frightened * * sleep disorder △ rests the head on bald △ △ and disappeared that still existing has disappeared and still exist and disappeared that still existing has disappeared still exists |
| Observation group's 31 1 34 0 27 11 24 matched groups 93 11 28108 |
* X
2=5．05 ** X
2=5．46
P＜0．05 P＜0．05
△X
2=0．76 △△X
2=0．33
P＜0．05 P＜0．05
(2) blood calcium, phosphorus, alkaline phosphorus enzyme etc. change (table 2) before and after the treatment
Have no significant change before and after two groups of patients' serium inorganic phosphorus, the alkaline phosphatase enzyme treatment
(P＜0.05) blood calcium is significant difference then.
The variation of two groups of infant blood calcium before and after table 2 treatment
| Matched group 0.15 ± 0.32 3.36＜0.05 observation group 0.23 ± 0.26 |
Seven checks are carried out with the difference of the preceding blood calcium of treatment in two groups of infant treatment backs, significant difference is arranged.
Routine blood test, routine urinalysis, liver, renal function, all no abnormal discovery of electrocardiogram before and after (four) two groups of infant treatments.
The curative effect of (five) two groups of therapeutic outcomes relatively
Table 4 liang group infant curative effect relatively
| The produce effects enabledisable |
| Observation group's 57.1% 40.0% 2.9% matched groups 33.3% 53.3% 13.4% |
As can be seen from the table, the curative effect of osteotrophy liquid obviously is better than calcium gluconate tablet.Discuss: rickets is a usual diseases of childhood, early discovery, and suitably treatment can reduce disability rate greatly.Therapeutic Method commonly used is oral calcium preparation or intravenous injection calcium gluconate, uses vitamin D simultaneously.But oral calcium tablet, absorbance is low; The intravenous injection calcium gluconate is difficult for being accepted by infant and family members, the osteotrophy liquid that this research is used promptly contains calcium and contains the calcium ion absorption enhancer again, through clinical verification, to compare with calcium gluconate, osteotrophy liquid can be eliminated child suffering from rickets's clinical symptoms significantly.Though the two all can make blood calcium raise, osteotrophy liquid is owing to can promote calcium absorption preferably, and institute is so that calcium level can have rising largely in the identical time.And infant routine blood test, routine urinalysis, hepatic and renal function, all no abnormal discovery of electrocardiogram after the treatment.
Six, conclusion
1, osteotrophy liquid has the obvious child suffering from rickets's of improvement symptom, and blood calcium is raise, and its curative effect obviously is better than calcium gluconate tablet.
2, the medication front and back are to blood, routine urinalysis, and the detection of hepatic and renal function shows that this medicine is without any side effects.
3, this medicine is a liquid dosage form, the infant taking convenience.
Clinical drug of the present invention uses the result to show that following advantage is arranged: human body had no side effect, and taking convenience, good absorbing raises blood calcium, and children rachitis, adult's osteoporosis are had obvious curative effects.
Embodiment 1
Select following ingredient and weight ratio thereof for use
5 parts of calcium gluconate
0.3 part of zinc gluconate
0.8 part in glutamic acid
In Agitation Tank, add deionized water, be heated to 100 ℃, pour described medicine in proportion into, stirring, dissolving, mixing, add deionized water again, making the Total Water that successively adds is 100: 5 with the part by weight of medicine, then with the sintered glass filter filtration of 80 μ m, fill becomes bottle, 10 milliliters every, the high pressure autoclaving, this is product of the present invention.
Embodiment 2
Select following pharmaceutical compositions and weight ratio thereof for use:
6 parts of activated calciums
0.4 part in zinc sulfate
1 part of glu famine
In irritating, dosing adds deionized water, be heated to 100 ℃, pour activated calcium, zinc sulfate, glutamine in described ratio, stirring, dissolving, mixing add deionized water again, the part by weight that makes Total Water and medicine is 100: 6, sintered glass filter with 120 μ m filters then, and fill becomes bottle, 10 milliliters every, microwave sterilizating, this is product of the present invention.
Claims (4)
1, a kind of medicine of preventing and treating treatment of calcium deficiency is characterized in that: it is the medicament of being made by the following weight proportion raw material:
4-8 parts of activated calciums
0.1-0.4 part of zinc gluconate
0.8-1.2 parts in glutamine or glutamic acid
2, a kind of medicine of preventing and treating treatment of calcium deficiency as claimed in claim 1 is characterized in that described medicament is powder or oral liquid.
3, a kind of medicine of preventing and treating treatment of calcium deficiency as claimed in claim 3, the part by weight that it is characterized in that oral liquid water and medicine is 100: 3-9.
4, a kind of medicine of preventing and treating treatment of calcium deficiency as claimed in claim 1, it is characterized in that in Agitation Tank, adding deionized water, be heated to 100 ℃, pour activated calcium, zinc gluconate, glutamine or glutamic acid in described ratio, stirring, dissolving, mixing add deionized water again, the part by weight that makes Total Water and medicine is 100: 3-9, use the sintered glass filter of 80-120 μ m to filter then, fill becomes bottle, High Temperature High Pressure or microwave sterilizating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95117811A CN1060336C (en) | 1995-12-05 | 1995-12-05 | Medicine for prevention and treatment of calcium deficiency and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95117811A CN1060336C (en) | 1995-12-05 | 1995-12-05 | Medicine for prevention and treatment of calcium deficiency and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1153634A CN1153634A (en) | 1997-07-09 |
| CN1060336C true CN1060336C (en) | 2001-01-10 |
Family
ID=5081361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95117811A Ceased CN1060336C (en) | 1995-12-05 | 1995-12-05 | Medicine for prevention and treatment of calcium deficiency and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1060336C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201713D0 (en) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
| PL368573A1 (en) * | 2004-06-17 | 2005-12-27 | Sgp & Sons Ab | Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals |
| PL370937A1 (en) * | 2004-10-29 | 2006-05-02 | Sgp & Sons Ab | Nutritional and/or pharmaceutical preparation for use in the prevention and treatment for the deficiency in absorption of microelements from the alimentary canal as well as application of pharmaceutical preparation stimulating absorption of microelements |
| CN114767719B (en) * | 2022-05-30 | 2023-01-17 | 北京朗迪制药有限公司 | A kind of pharmaceutical composition for preventing and treating rickets and its preparation method |
| CN115089618B (en) * | 2022-05-30 | 2023-03-17 | 北京朗迪制药有限公司 | A pharmaceutical composition for preventing and treating osteoporosis, and its preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085425A (en) * | 1992-10-13 | 1994-04-20 | 张业华 | The production of calcium treasured |
| CN1091007A (en) * | 1993-12-03 | 1994-08-24 | 北京市三喜化学新技术公司 | High nutrition, high curative effect, easy novel calcium preparation---the nanometer calcium (calcium king) that absorbs |
| CN1110714A (en) * | 1995-03-01 | 1995-10-25 | 秦九忱 | Nutrition health-care beer and its production method |
-
1995
- 1995-12-05 CN CN95117811A patent/CN1060336C/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085425A (en) * | 1992-10-13 | 1994-04-20 | 张业华 | The production of calcium treasured |
| CN1091007A (en) * | 1993-12-03 | 1994-08-24 | 北京市三喜化学新技术公司 | High nutrition, high curative effect, easy novel calcium preparation---the nanometer calcium (calcium king) that absorbs |
| CN1110714A (en) * | 1995-03-01 | 1995-10-25 | 秦九忱 | Nutrition health-care beer and its production method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1153634A (en) | 1997-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004292428B2 (en) | Colonic purgative composition with soluble binding agent | |
| CN1149255A (en) | Use of magnesium-based products for the treatment or prevention of tumors and autoimmune diseases | |
| KR0145715B1 (en) | N-acetyl glucosamine as a cytoprotective agent | |
| JP2012121914A (en) | Alleviator for radiation disorder | |
| JP5025847B2 (en) | Diabetes treatment | |
| CN1060336C (en) | Medicine for prevention and treatment of calcium deficiency and its prepn | |
| WO2012050483A1 (en) | Method for producing and using a copolymer of sodium carboxymethyl cellulose and gossypol | |
| CN1074762C (en) | Process for preparing chromium L-threonate, its preparing process and application | |
| CN1086289C (en) | Medicine for treating diabetes and nephrosis containing rheinic acid | |
| CN1239156C (en) | Oral Solution for preventing and treating acalcerosis and its prepn process | |
| CN101607080B (en) | Oral drug for treating diabetes and preparation method thereof | |
| SU1632428A1 (en) | Method for treatment heavy cranio-cerebral trauma during acute disease period | |
| CN1850112B (en) | polyethylene glycol-electrolyte oral solution | |
| CN1301109C (en) | Calcium, zinc and ferrum composite oral liquor and its preparing process | |
| CN1061256C (en) | Hypertension ointment for external use | |
| CN105935443A (en) | Pharmaceutical composition for treating diabetic cataract | |
| CN1168462C (en) | An oral solution capable of lowering blood fat and improving symptoms of myocardial ischemia and myocardial infarction | |
| CN101804068B (en) | Polyethylene glycol-electrolyte oral solution | |
| CN105147623A (en) | Oral lactulose lyophilized powder and preparation method thereof | |
| CN1120725C (en) | Medicine for treating osteoporosis and hyperosteogeny and preparation process thereof | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN103948591B (en) | A kind of slimming agents | |
| CN1027959C (en) | Zinc-calcium oral liquid and its preparation method | |
| CN1748771A (en) | Chinese medicine composition for treating diabetes and its preparing method and use | |
| CN1537603A (en) | Traditional Chinese medicine navel plaster, and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20070312 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20080912 Pledge (preservation): Preservation registration |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20090120 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20090720 Pledge (preservation): Preservation registration |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20090721 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20091021 Pledge (preservation): Preservation registration |
|
| C35 | Partial or whole invalidation of patent or utility model | ||
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20100611 Decision number of declaring invalidation: 14944 Granted publication date: 20010110 |
|
| C35 | Partial or whole invalidation of patent or utility model | ||
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20100611 Decision number of declaring invalidation: 14945 Granted publication date: 20010110 |